drugset / Trial / NCT00983021

Safety and Tolerability of NN9068 in Healthy Male Volunteers

NCT00983021

Phase 1 Completed 24 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068. The trial participants will be randomised to 4 different treatments in trial, receiving trial products in a pre-defined order.

Timeline

Start
2009-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide Subcutaneous
Subject insulin degludec Protein / enzyme biologic Subcutaneous

Indications